The Neuralink Rival That Just Raised $230M to Fix Blindness

The round was led by Lightspeed Venture Partners, one of Silicon Valley's most prominent firms, with participation from Khosla Ventures. But the investor list gets more interesting from there.

Y Combinator participated, which makes sense given the startup pedigree. Quiet Capital joined as well. And then there's IQT (In-Q-Tel), the nonprofit investment arm affiliated with U.S. intelligence agencies like the CIA.

Yes, you read that right. The intelligence community's venture fund is investing in retinal implants.

That might sound surprising, but IQT has a long history of backing technologies with both civilian and strategic applications. Brain-computer interfaces, sensor technologies, and advanced optics all fall squarely in their wheelhouse. Their involvement signals that Science Corporation's technology has implications well beyond eye clinics.

The Race to Market

Here's where the timeline gets exciting. Science Corporation has already submitted a CE mark application to the European Union and expects approval by mid-2026. Germany is likely the first market, thanks to its established early access pathways for medical devices.

Simultaneously, the company is in regulatory discussions with the FDA for U.S. approval. If the European launch goes smoothly, it could build the kind of real-world evidence that greases the wheels stateside.

This is a playbook we've seen before in medtech: launch in Europe first, collect data, then use that momentum to accelerate the American regulatory process. It's the equivalent of testing your restaurant concept in a smaller market before opening on Fifth Avenue.

Not Just Eyes

The $230 million isn't all going toward PRIMA. Science Corporation has two other ambitious programs that hint at a much bigger vision (no pun intended).

First, there's a biohybrid neural interface program. The concept sounds like science fiction: engineered neurons grown directly onto devices that then interface with brain tissue. If PRIMA is the company's first act, this is where the Neuralink comparison becomes most direct. They're building toward broader brain-computer interfaces, just taking a different technological path to get there.

Second, the company launched a new business unit called Vessel, focused on organ preservation and transport technology. That might seem like a left turn, but it actually shares underlying biology with their core work. Keeping cells alive and functional outside the body is a challenge that connects neural interfaces, retinal implants, and organ transport.

Why This Round Matters for Biotech

Let's zoom out. A $230 million Series C is significant in any year. In 2026, it's especially notable.

The biotech venture landscape has been recovering from a brutal 2022-2023 correction. U.S. biopharma startups raised $26 billion across 416 rounds in a recent annual period, featuring fewer but larger deals. The trend is clear: investors are concentrating bigger bets on companies they believe in, rather than spreading money thinly across dozens of early-stage bets.

For context, Soley Therapeutics raised $200 million in January 2026 for oncology. Science Corporation's $230 million sits comfortably in that upper tier.

The broader signal? Growth-stage private funding is alive and well, but it's increasingly reserved for companies with clear paths to commercialization. Science Corporation checks that box: they have a defined product, a regulatory submission already filed, and a market launch potentially months away.

The Bottom Line

Science Corporation is doing something genuinely rare in biotech. They're bridging the gap between futuristic brain-computer interface research and near-term medical products that could help real patients this year.

The $1.5 billion valuation might look rich for a pre-revenue company, but consider what they're actually selling: the possibility of restoring sight to people who thought they'd never see clearly again. If PRIMA delivers on its promise, this valuation will look like a bargain in hindsight.

Max Hodak left Neuralink to build something different. With $490 million in total funding, regulatory submissions in progress, and the intelligence community writing checks, it's getting harder to bet against him.

Alnylam Just Bet $1.1 Billion on a Tiny Heart Disease Company

Alnylam just inked a deal worth up to $1.13 billion with tiny cardiac biotech Tenaya Therapeutics to hunt for new heart disease gene targets. It's the latest sign that RNA medicine is coming for cardiology's biggest problems.